Is Egrifta (Tesamorelin) Legal in North Carolina?

The Short Legal Answer

Egrifta (tesamorelin) is legal in North Carolina for patients who hold a valid prescription from a licensed prescriber. The drug received FDA approval on November 10, 2010, making it a lawful Schedule-free prescription medication under the federal Food, Drug, and Cosmetic Act. North Carolina General Statute 90-85.27 governs pharmacy practice in the state but adds no tesamorelin-specific restrictions beyond what federal law already requires.

The short version: get a prescription, fill it at a licensed pharmacy, and you are fully within the law.

What "Legal" Actually Means Here

Legal status for a prescription drug in the United States operates on two layers: federal and state.

At the federal level, the FDA regulates whether a drug may be manufactured, marketed, and dispensed. Tesamorelin passed that bar in 2010 under NDA 022505. The FDA approval record is publicly searchable on the agency's Drugs@FDA database.

At the state level, North Carolina's Medical Practice Act (G.S. Chapter 90, Article 1) and the North Carolina Board of Pharmacy (G.S. Chapter 90, Article 4A) govern prescribing and dispensing. Neither statute calls out tesamorelin by name, and neither adds scheduling or special-permit requirements for this compound.

What Does Not Make It Legal

Purchasing tesamorelin from an overseas website, a research-chemical vendor, or any outlet that does not require a prescription violates the federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331. That violation applies equally to North Carolina residents regardless of how a vendor labels its product.

FDA Approval: The Foundation of Tesamorelin's Legal Status

Tesamorelin's entire legal framework rests on its FDA approval. Understanding that approval clarifies both what is permitted and where the legal gray areas begin.

NDA 022505 and the Approved Indication

The FDA approved Egrifta on November 10, 2010, based on two Phase 3 randomized controlled trials (LIPO-010 and LIPO-020, combined N=816) that demonstrated statistically significant reductions in visceral adipose tissue in HIV-positive adults receiving antiretroviral therapy. Published data in NEJM (Falutz et al., 2010) showed a mean trunk fat reduction of 18.4% vs. 5.0% placebo at 26 weeks, P<0.001. [1]

The approved indication is narrow: reduction of excess abdominal fat in HIV-positive adults with lipodystrophy. Prescribing it outside that indication is legal (physicians may prescribe off-label) but insurers generally will not cover off-label use, and the FDA does not authorize manufacturers to market it for other purposes.

Egrifta SV: The Current Formulation

Theratechnologies reformulated the product as Egrifta SV (2 mg/vial, stable in liquid form) in 2019. The original lyophilized Egrifta (1 mg) is no longer actively marketed in the United States. When your prescriber writes for Egrifta, the dispensed product is the SV formulation. The current prescribing information is on the FDA label database. [2]

Tesamorelin as a GHRH Analogue: Why People Seek It Off-Label

Tesamorelin is a stabilized analogue of endogenous growth hormone-releasing hormone (GHRH). By binding pituitary GHRH receptors, it drives a pulsatile, physiologic release of growth hormone rather than the supraphysiologic bolus produced by exogenous GH injections. Researchers have studied it for non-HIV metabolic applications, including a 2018 Annals of Internal Medicine trial (N=152) showing cognitive benefits in older adults with mild cognitive impairment. That trial found a statistically significant improvement on a composite functional memory score vs. Placebo at 20 weeks, P<0.001. [3] Those data drive off-label interest, but they do not change the FDA-approved indication.

Compounded Tesamorelin in North Carolina: The Gray Zone

Brand Egrifta is straightforward. Compounded tesamorelin is more complicated. Here is where most patients and prescribers run into confusion.

Federal 503A and 503B Compounding Rules

The Drug Quality and Security Act of 2013 created two compounding pathways:

503A pharmacies are traditional compounding pharmacies that produce patient-specific preparations. Under 21 U.S.C. § 353a, a 503A pharmacy may compound a drug that is not a copy of a commercially available product and is not a bulk drug substance on the FDA's list of substances that may not be used in compounding.

503B outsourcing facilities produce larger-volume, non-patient-specific batches for healthcare providers. They operate under cGMP standards and may only use bulk drug substances on the FDA's 503B bulk-drug substances list, or substances under active evaluation.

Where Tesamorelin Stands on the Bulk Lists

Tesamorelin is an FDA-approved drug with a commercially available reference listed drug (Egrifta SV). That status creates a legal tension for compounders: a 503A pharmacy generally cannot compound a drug that is "essentially a copy" of an approved commercially available drug unless a prescriber documents a specific clinical difference needed for the individual patient (e.g., a documented allergy to an excipient in Egrifta SV). The FDA's guidance on compounding and the "essentially a copy" standard is publicly available on the FDA website. [4]

As of the date of this article's last review, tesamorelin does not appear on the FDA's 503B bulk-drug substances list (the "Category 1" or "Category 2" lists) as an affirmatively nominated and evaluated compound available for unrestricted outsourcing facility use. The FDA's current 503B bulk-drug substances list can be verified directly. [5]

The practical consequence is a three-tier legal picture for North Carolina patients:

| Access Path | Legal Status | Prescription Required | |---|---|---| | Brand Egrifta SV from a licensed retail or specialty pharmacy | Fully legal | Yes | | Compounded tesamorelin from a 503A pharmacy with documented clinical rationale | Legally defensible with proper documentation | Yes | | Compounded tesamorelin from a 503B outsourcing facility | Not clearly authorized under current bulk-list status | Yes | | Tesamorelin purchased without a prescription (online, research vendors) | Federal violation | N/A |

North Carolina Board of Pharmacy Position

The North Carolina Board of Pharmacy (NCBOP) enforces state pharmacy law and defers to federal cGMP and DQSA standards for compounding. The NCBOP publishes a list of registered out-of-state pharmacy permit holders that may ship into North Carolina. Any 503A pharmacy filling a tesamorelin compound for a North Carolina patient must hold either a North Carolina pharmacy permit or a valid non-resident pharmacy permit recognized by the NCBOP. The NCBOP's permit verification tool is available through the board's official site, which references applicable statutes under G.S. 90-85.21A.

How to Get a Legal Tesamorelin Prescription in North Carolina

North Carolina patients who meet the FDA-approved indication or who have a compelling off-label clinical rationale have several legitimate pathways to access tesamorelin.

Path 1: In-Person Specialist Visit

An endocrinologist, infectious disease specialist, or internist licensed in North Carolina can evaluate HIV-associated lipodystrophy and write a prescription for Egrifta SV. The prescription can be filled at specialty pharmacies (many specialty pharmacies ship within North Carolina) that carry brand Egrifta. Insurance coverage through Medicaid, most commercial plans, and the AIDS Drug Assistance Program (ADAP) is available for the approved indication.

Typical starter dose per the FDA label: tesamorelin 2 mg subcutaneously once daily. The prescriber should reassess visceral fat reduction at 26 weeks and discontinue if there is no meaningful response. [2]

Path 2: Telehealth Prescription

North Carolina law explicitly permits synchronous audio-video telehealth consultations and authorizes prescribing following a telehealth encounter under G.S. 90-18.5 and the North Carolina Medical Board's "Appropriate Use of Telemedicine Technologies in the Practice of Medicine" policy. A physician or advanced practice provider conducting a telehealth visit may prescribe Egrifta SV if they form a valid patient-provider relationship and document the clinical indication.

The North Carolina Medical Board issued guidance in 2022 clarifying that prescribing standards for telehealth encounters are identical to in-person encounters. "A physician who uses telemedicine technologies shall be held to the same standards of appropriate practice as those applicable in traditional in-person practice settings," the Board's policy states. [6]

Telehealth platforms specializing in hormone therapy (including HealthRX) can connect North Carolina patients with licensed prescribers who evaluate tesamorelin candidacy as part of a comprehensive metabolic or HIV care workup.

Path 3: Off-Label Prescription With Clinical Documentation

A physician may legally prescribe Egrifta SV off-label (for example, for non-HIV metabolic dysfunction with documented GH axis insufficiency), provided they document the clinical rationale in the medical record. Off-label prescribing of FDA-approved drugs is legal under federal law and North Carolina's Medical Practice Act. The prescriber assumes responsibility for demonstrating that the use is medically appropriate.

Patients pursuing off-label tesamorelin should expect to pay out-of-pocket, as payers rarely cover off-label peptide therapy.

What to Bring to Your Appointment

A productive first visit for tesamorelin evaluation should include:

• Fasting IGF-1 level (to characterize the GH axis at baseline)
• A DEXA scan or CT measurement of visceral adipose tissue if lipodystrophy is the indication
• A complete metabolic panel (tesamorelin can increase glucose and HbA1c; the FDA label notes a small but measurable increase in fasting glucose in Phase 3 trials) [2]
• Documentation of HIV status and current antiretroviral regimen if seeking the approved indication
• A list of current medications (tesamorelin induces CYP3A4 and may reduce plasma levels of some antiretrovirals)

Safety, Monitoring, and Legal Prescribing Obligations

Legal access is only one part of responsible tesamorelin use. Prescribers in North Carolina are obligated by the Medical Practice Act and standard of care to monitor patients appropriately.

FDA-Required Monitoring Points

The Egrifta SV prescribing information specifies several monitoring requirements that responsible prescribers must document: [2]

• Glucose tolerance: baseline HbA1c and fasting glucose before starting; reassess at 3 months and annually. Tesamorelin carries a contraindication in patients with active malignancy and a warning for fluid retention and glucose intolerance.
• IGF-1 levels: the label does not mandate a specific IGF-1 target, but many endocrinologists use IGF-1 as an indirect marker of GH response during therapy.
• Discontinuation rule: if a patient does not achieve a meaningful reduction in visceral fat by 26 weeks, the drug should be stopped per the labeling.

Contraindications in the FDA Label

Absolute contraindications listed in Egrifta SV's prescribing information include: active malignancy or history of malignancy (excluding basal cell or localized squamous cell carcinoma of the skin), hypersensitivity to tesamorelin or mannitol, pregnancy, and disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor, hypophysectomy, pituitary irradiation, traumatic brain injury). [2]

A licensed North Carolina prescriber who fails to screen for these contraindications before prescribing faces both medical liability and potential Medical Board scrutiny.

What "Off-Label" Does Not Protect

Off-label prescribing is legal, but it does not shield a prescriber from negligence claims if the prescription is clinically unsupported. The AACE Clinical Practice Guidelines for Growth Hormone Deficiency note that GH-axis peptide therapy should be grounded in objective biochemical evidence of deficiency, not subjective symptoms alone. [7] A North Carolina prescriber who writes tesamorelin based solely on a patient's request, without documented clinical reasoning, could face Medical Board action under G.S. 90-14(a)(6), which covers prescribing without clinical justification.

Purchasing Tesamorelin Without a Prescription: Federal and State Exposure

Some patients attempt to bypass the prescription requirement by purchasing tesamorelin from overseas pharmacies, peptide research vendors, or gray-market websites. This is illegal. No ambiguity exists here.

Under 21 U.S.C. § 331(a), introducing a misbranded or unapproved new drug into interstate commerce is prohibited. A product labeled "tesamorelin for research use only, not for human use" is still a drug under FDA jurisdiction if sold with the implicit understanding that buyers will inject it. The FDA has issued multiple warning letters to peptide research vendors making this exact argument. [8]

North Carolina does not add state criminal penalties for simple possession of a non-controlled prescription drug obtained without a prescription, but a patient carrying injectable tesamorelin without documentation of a valid prescription has no legal defense if questioned about the drug's origin.

The risk profile is not just legal. Products sold by unregulated vendors carry no quality assurance. A 2020 FDA analysis of compounded peptide products found contamination, incorrect concentrations, and non-sterile conditions across multiple sampled lots.

Insurance Coverage and Cost in North Carolina

Brand Egrifta SV costs approximately $5,000 to $8,000 per month at list price without insurance. That figure makes coverage navigation a practical necessity for most patients.

Covered Uses

For HIV-positive patients with documented lipodystrophy, coverage pathways include:

• Medicaid (NC Medicaid Managed Care): Egrifta SV is covered under NC Medicaid fee-for-service and managed care plans when prior authorization documents the HIV indication and baseline visceral fat measurement. Criteria follow the FDA label.
• Commercial insurance: Most major payers (BCBS NC, Aetna, Cigna, UnitedHealthcare) cover Egrifta SV for the approved indication with prior authorization. Step-therapy requirements (requiring failure of lifestyle intervention first) are common.
• ADAP (AIDS Drug Assistance Program): North Carolina operates an ADAP program through the Division of Public Health. Egrifta SV is on the NC ADAP formulary for eligible HIV-positive patients below 300% of the federal poverty level.

Off-Label Cost Reality

Off-label use is almost never covered by insurance. Patients pursuing tesamorelin for non-HIV indications should budget for full out-of-pocket cost. Compounded tesamorelin, where legally available from a 503A pharmacy with documented clinical rationale, may cost significantly less ($200 to $600 per month depending on dose and pharmacy). Confirm the compounding pharmacy holds a valid North Carolina or non-resident pharmacy permit before placing an order.

Frequently Asked Questions